Journal of Clinical Oncology, Vol 6, 26-33, Copyright © 1988 by American Society of Clinical Oncology

ARTICLES

Lymphoblastic lymphoma in children--a randomized trial comparing LSA2- L2 with the A-COP+ therapeutic regimen: a Pediatric Oncology Group Study

EV Hvizdala, C Berard, T Callihan, J Falletta, H Sabio, JJ Shuster, M Sullivan and MD Wharam
University of South Florida, Tampa.

From May 1979 to March 1983, 76 evaluable patients with lymphoblastic lymphoma (LBL) were treated by members of the Pediatric Oncology Group (POG). Forty-six children treated by the six-drug A-COP+ regimen (Adriamycin [doxorubicin; Adria Laboratories, Columbus, OH], vincristine, prednisone, cyclophosphamide, methotrexate, and hydrocortisone) were compared in a prospective randomized trial with 30 patients receiving the modified ten-drug LSA2-L2 (cyclosphosphamide, vincristine, methotrexate, Daunomycin [daunorubicin cerubidine; Wyeth Laboratories, Philadelphia], prednisone, cytarabine, thioguanine, asparaginase, hydroxyurea, and carmustine) regimen. After adjusting for stage (I and II v III v IV), there was no statistically significant difference (P = .19) between A-COP+ and LSA2-L2 regimens on the basis of 3-year survival and disease-free survival (62% v 72% and 53% v 58%, respectively for the two treatment regimens) but the power of analysis and thus the ability to detect a clinically meaningful difference in the outcome with the two regimens was limited by the small number of patients. Neither therapy was effective for most patients with stage IV disease, with failure occurring in six of seven children receiving A- COP+ regimen and eight of 11 patients receiving LSA2-L2. Although the LSA2-L2 regimen was more toxic during the induction of remission, the toxicity during maintenance was acceptable and similar for both treatments. CNS relapse was not a significant problem whether cranial radiation with intrathecal (IT) therapy (A-COP+) or IT therapy alone (LSA2-L2) were used. Our results confirm the overall effectiveness of the LSA2-L2 regimen in children with LBLs, especially those initially free of bone marrow or CNS involvement, but were inconclusive as to the inferiority or superiority of this regimen over the A-COP+ regimen.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Reiter, M. Schrappe, W.-D. Ludwig, M. Tiemann, R. Parwaresch, M. Zimmermann, E. Schirg, G. Henze, G. Schellong, H. Gadner, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM Group report Blood, January 15, 2000; 95(2): 416 - 421. [Abstract] [Full Text] [PDF]

				M. P. Link, J. J. Shuster, S. S. Donaldson, C. W. Berard, and S. B. Murphy Treatment of Children and Young Adults with Early-Stage Non-Hodgkin's Lymphoma N. Engl. J. Med., October 30, 1997; 337(18): 1259 - 1266. [Abstract] [Full Text] [PDF]

				J. T. Sandlund, J. R. Downing, and W. M. Crist Non-Hodgkin's Lymphoma in Childhood N. Engl. J. Med., May 9, 1996; 334(19): 1238 - 1248. [Full Text] [PDF]

				E. Ward and C. A. Gushurst Uses and Technique of Pediatric Lumbar Puncture Arch Pediatr Adolesc Med, October 1, 1992; 146(10): 1160 - 1165. [Abstract] [PDF]